Can Teva Rebound After This Rejection?
Teva Pharmaceutical Industries received some bad news last week after its oral multiple sclerosis drug laquinimod received a negative opinion by the EU's CHMP. In this video, Motley Fool health-care analyst Max Macaluso takes a look at what this decision means for Teva today, and where the company needs to strategically go from here following this decision.
Get this stock pick on your radar today
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report, "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
The article Can Teva Rebound After This Rejection? originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
